CEACAM5 and neoplasm: The data presented here provide the first evidence that the canonical biomarker CEA, which is used for monitoring tumor growth of adenocarcinomas as well as treatment efficacy, might have not only a biological role, but could provide a predictive function for anti-VEGF-based combination therapies.